Nabriva Therapeutics Stock Performance
Shares of Nabriva Therapeutics stock opened at $0.35 on Friday. Nabriva Therapeutics has a one year low of $1.22 and a one year high of $8.45. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. The company has a market cap of $11.21 million, a price-to-earnings ratio of -0.02 and a beta of 1.53. The business’s 50 day moving average price is $0.44 and its 200 day moving average price is $1.00.
Institutional Investors Weigh In On Nabriva Therapeutics
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC raised its holdings in Nabriva Therapeutics plc (NASDAQ:NBRV – Free Report) by 102.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 795,938 shares of the biotechnology company’s stock after purchasing an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned 0.13% of Nabriva Therapeutics worth $145,000 as of its most recent SEC filing. 0.27% of the stock is owned by hedge funds and other institutional investors.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.
- Five stocks we like better than Nabriva Therapeutics
- What is Insider Trading? What You Can Learn from Insider Trading
- The most upgraded stocks in November have two things in common
- Financial Services Stocks Investing
- Monday.com rocked earnings like it’s the weekend
- What Investors Need to Know to Beat the Market
- Plan to own one retailer? Make it this one
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.